TM-38837 is a small molecule inverse agonist/antagonist of the CB1 cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma. The company has announced phase I clinical trials. TM-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB1 receptor antagonists such as rimonabant.
Property | Value |
---|---|
dbo:abstract |
|
dbo:casNumber |
|
dbo:pubchem |
|
dbo:thumbnail | |
dbo:wikiPageExternalLink | |
dbo:wikiPageID |
|
dbo:wikiPageLength |
|
dbo:wikiPageRevisionID |
|
dbo:wikiPageWikiLink |
|
dbp:atcPrefix |
|
dbp:c |
|
dbp:casNumber |
|
dbp:chemspiderid |
|
dbp:cl |
|
dbp:f |
|
dbp:h |
|
dbp:iupacName |
|
dbp:n |
|
dbp:o |
|
dbp:pubchem |
|
dbp:s |
|
dbp:smiles |
|
dbp:stdinchi |
|
dbp:stdinchikey |
|
dbp:width |
|
dbp:wikiPageUsesTemplate | |
dcterms:subject | |
gold:hypernym | |
rdf:type |
|
rdfs:comment |
|
rdfs:label |
|
owl:sameAs | |
prov:wasDerivedFrom | |
foaf:depiction | |
foaf:isPrimaryTopicOf | |
is dbo:wikiPageRedirects of | |
is dbo:wikiPageWikiLink of | |
is foaf:primaryTopic of |